ImmunoCellular Therapeutics (IMUC) Reports Q4 Loss of $1.23/Share

ImmunoCellular Therapeutics (NYSE: IMUC) reported Q4 EPS of ($1.23), versus ($7.89) reported last year.

For earnings history and earnings-related data on ImmunoCellular Therapeutics (IMUC) click here.

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Ubiquiti (UI) Tops Q4 EPS by 25c, Beats on Revenue